C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/11 (2006.01) A61K 31/00 (2006.01) A61K 31/38 (2006.01) A61K 31/40 (2006.01) A61K 31/445 (2006.01) A61K 31/55 (2006.01) C07K 14/46 (2006.01) C07K 14/495 (2006.01) C07K 14/72 (2006.01) C12N 5/10 (2006.01) C12N 15/85 (2006.01) C12Q 1/48 (2006.01) C12Q 1/66 (2006.01) C12Q 1/68 (2006.01)
Patent
CA 2126294
ABSTRACT OF THE INVENTION The present invention relates to methods for the identification of therapeutic agents for the treatment of osteoporosis and serum lipid lowering agents. The invention relates to isolating cloning, and using nucleic acids from the promoter regions of transforming growth factor .beta. genes comprising novel regulatory elements designated "raloxifene responsive elements". The invention also encompasses eukaryotic cells containing such raloxifene responsive elements operably linked to reporter genes such that the raloxifene responsive elements modulate the transcription of the reporter genes. The invention provides methods for identifying anti-osteoporosis agents that induce transcription of genes operably linked to such raloxifene responsive elements without inducing deleterious or undesirable side effects associated with current anti- osteoporosis therapy regimens.
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Materials and methods for screening anti-osteoporosis agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Materials and methods for screening anti-osteoporosis agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Materials and methods for screening anti-osteoporosis agents will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1647297